Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes.

Wenzl, Florian A; Bruno, Francesco; Kraler, Simon; Klingenberg, Roland; Akhmedov, Alexander; Ministrini, Stefano; Santos, Karine; Godly, Konstantin; Godly, Julia; Niederseer, David; Manka, Robert; Bergmann, Andreas; Camici, Giovanni G; von Eckardstein, Arnold; Stähli, Barbara; Muller, Olivier; Roffi, Marco; Räber, Lorenz; Lüscher, Thomas F (2023). Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes. European heart journal, 44(38), pp. 3859-3871. Oxford University Press 10.1093/eurheartj/ehad545

Text Dipeptidyl_peptidase_3_plasma_levels_predict_cardiogenic_shock_and_mortality_in_acute_coronary_syndromes.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) | Request a copy

BACKGROUND AND AIMS

Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of angiotensin II which disturbs peripheral blood pressure regulation and compromises left ventricular function. This study examined the relationship of circulating DPP3 (cDPP3) with cardiogenic shock (CS) and mortality in patients presenting with acute coronary syndromes (ACS).

METHODS

Plasma cDPP3 levels were assessed at baseline and 12-24 h after presentation in patients with ACS prospectively enrolled into the multi-centre SPUM-ACS study (n = 4787).

RESULTS

Circulating DPP3 levels were associated with in-hospital CS when accounting for established risk factors including the ORBI risk score [per log-2 increase, hazard ratio (HR) 1.38, 95% confidence interval (CI) 1.05-1.82, P = .021]. High cDPP3 was an independent predictor of mortality at 30 days (HR 1.87, 95% CI 1.36-2.58, P < .001) and at one year (HR 1.61, 95% CI 1.28-2.02, P < .001) after adjustment for established risk factors and the GRACE 2.0 score. Compared to values within the normal range, persistently elevated cDPP3 levels at 12-24 h were associated with 13.4-fold increased 30-day mortality risk (HR 13.42, 95% CI 4.86-37.09, P < .001) and 5.8-fold increased 1-year mortality risk (HR 5.79, 95% CI 2.70-12.42, P < .001). Results were consistent across various patient subgroups.

CONCLUSIONS

This study identifies cDPP3 as a novel marker of CS and increased mortality in patients with ACS. Circulating DPP3 offers prognostic information beyond established risk factors and improves early risk assessment.

Interest & Impact

Downloads

0 since deposited on 29 Dec 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item